Gland Pharma Limited — Q1FY27 earnings call summary

Filed 10 August 2026 · Company audio recording

Long-term 4-5 year CAGR guidance around 20%, driven by CDMO expansion and new product launches.
Multiple brownfield and greenfield capacity expansions underway, including oncology isolated line (Rs. 165 cr CAPEX) and new vial, BFS, ophthalmic lines.
CDMO expected to remain ~50% of revenue near term; aiming for 30% EBITDA margin in near term, 35% longer term.
FY27 Q1 revenue grew 20% YoY to Rs. 18,003 mn; constant currency growth at 15%.
Targeting ~15% revenue growth for FY27 with potential upside if new FDA approvals come timely.
Q1 adjusted EBITDA margin improved to 28% from 25% YoY, driven by favorable product mix, higher CDMO share, operational efficiencies, and cost optimization.
GLP-1 CDMO line on track; commercialization expected post-FY29 with limited near-term revenue.
FDA approval timelines for new lines (e.g., back line) critical for upside in FY27 growth.